Plain-English translation of NCT06137040 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
When children arrive at the emergency department with a moderate asthma attack, doctors typically give them bronchodilators (inhalers) and steroids right away. This study is testing whether adding magnesium sulfate intravenously during the first hour of care—alongside these standard treatments—helps children improve more quickly. Researchers want to know if getting this medication faster makes a difference in how long children stay in the hospital or whether they need additional respiratory support.
Magnesium sulfate is already sometimes used to treat severe asthma attacks, but doctors don't always give it right away. This trial is designed to find out whether administering this treatment earlier—within the first hour—could help children recover faster and reduce their time in the hospital.
You likely qualify if…
You likely don't qualify if…
If you qualify and your parent or caregiver consents, you'll be randomly assigned to one of two groups. One group will receive magnesium sulfate intravenously during the first hour alongside your regular asthma treatments; the other group will receive standard care, with magnesium given later only if your doctor decides it's necessary. Researchers will then track how long you stay in the emergency department and hospital, whether you need extra breathing support, and your overall recovery.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States